CN107050148B - Traditional Chinese medicine composition for dispelling effects of alcohol and protecting liver and preparation method thereof - Google Patents
Traditional Chinese medicine composition for dispelling effects of alcohol and protecting liver and preparation method thereof Download PDFInfo
- Publication number
- CN107050148B CN107050148B CN201710443629.7A CN201710443629A CN107050148B CN 107050148 B CN107050148 B CN 107050148B CN 201710443629 A CN201710443629 A CN 201710443629A CN 107050148 B CN107050148 B CN 107050148B
- Authority
- CN
- China
- Prior art keywords
- parts
- group
- composition
- extract
- ethanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 title claims abstract description 130
- 239000000203 mixture Substances 0.000 title claims abstract description 90
- 230000000694 effects Effects 0.000 title claims abstract description 48
- 239000003814 drug Substances 0.000 title claims abstract description 38
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 210000004185 liver Anatomy 0.000 title abstract description 32
- 239000000284 extract Substances 0.000 claims abstract description 75
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims abstract description 35
- 241000723353 Chrysanthemum Species 0.000 claims abstract description 34
- 235000007516 Chrysanthemum Nutrition 0.000 claims abstract description 34
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims abstract description 28
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims abstract description 28
- 239000000811 xylitol Substances 0.000 claims abstract description 28
- 229960002675 xylitol Drugs 0.000 claims abstract description 28
- 235000010447 xylitol Nutrition 0.000 claims abstract description 28
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 24
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 24
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims abstract description 18
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims abstract description 18
- 235000009685 Crataegus X maligna Nutrition 0.000 claims abstract description 18
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims abstract description 18
- 235000009486 Crataegus bullatus Nutrition 0.000 claims abstract description 18
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims abstract description 18
- 235000009682 Crataegus limnophila Nutrition 0.000 claims abstract description 18
- 235000004423 Crataegus monogyna Nutrition 0.000 claims abstract description 18
- 235000002313 Crataegus paludosa Nutrition 0.000 claims abstract description 18
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims abstract description 18
- 239000000843 powder Substances 0.000 claims abstract description 13
- 238000000605 extraction Methods 0.000 claims abstract description 11
- 238000010992 reflux Methods 0.000 claims abstract description 11
- 239000007788 liquid Substances 0.000 claims abstract description 7
- 239000002994 raw material Substances 0.000 claims abstract description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 7
- 240000000171 Crataegus monogyna Species 0.000 claims abstract 5
- 244000010000 Hovenia dulcis Species 0.000 claims description 27
- 235000008584 Hovenia dulcis Nutrition 0.000 claims description 27
- 108010003415 Aspartate Aminotransferases Proteins 0.000 claims description 13
- 102000004625 Aspartate Aminotransferases Human genes 0.000 claims description 13
- 230000002401 inhibitory effect Effects 0.000 claims description 7
- 210000000582 semen Anatomy 0.000 claims description 6
- 230000002159 abnormal effect Effects 0.000 claims description 3
- 101710088194 Dehydrogenase Proteins 0.000 claims 1
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 claims 1
- 239000008183 oral pharmaceutical preparation Substances 0.000 claims 1
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 abstract description 48
- 108010081577 aldehyde dehydrogenase (NAD(P)+) Proteins 0.000 abstract description 32
- 102000007698 Alcohol dehydrogenase Human genes 0.000 abstract description 29
- 108010021809 Alcohol dehydrogenase Proteins 0.000 abstract description 29
- 210000002966 serum Anatomy 0.000 abstract description 25
- 241000699670 Mus sp. Species 0.000 abstract description 20
- 208000007848 Alcoholism Diseases 0.000 abstract description 9
- 201000007930 alcohol dependence Diseases 0.000 abstract description 8
- 241000219780 Pueraria Species 0.000 abstract description 7
- 210000005228 liver tissue Anatomy 0.000 abstract description 7
- 239000000463 material Substances 0.000 abstract description 7
- 235000013305 food Nutrition 0.000 abstract description 6
- 206010067125 Liver injury Diseases 0.000 abstract description 4
- 235000013373 food additive Nutrition 0.000 abstract description 2
- 239000002778 food additive Substances 0.000 abstract description 2
- 239000000825 pharmaceutical preparation Substances 0.000 abstract description 2
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- BFBPISPWJZMWJN-UHFFFAOYSA-N methyl 2-[(7-hydroxy-3,7-dimethyloctylidene)amino]benzoate Chemical compound COC(=O)C1=CC=CC=C1N=CCC(C)CCCC(C)(C)O BFBPISPWJZMWJN-UHFFFAOYSA-N 0.000 abstract 2
- 231100000234 hepatic damage Toxicity 0.000 abstract 1
- 230000008818 liver damage Effects 0.000 abstract 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 33
- 230000000052 comparative effect Effects 0.000 description 24
- 229940079593 drug Drugs 0.000 description 22
- 239000013641 positive control Substances 0.000 description 17
- 235000020717 hawthorn extract Nutrition 0.000 description 15
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 14
- 108010082126 Alanine transaminase Proteins 0.000 description 14
- 241001092040 Crataegus Species 0.000 description 13
- 230000004060 metabolic process Effects 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 12
- 239000004375 Dextrin Substances 0.000 description 9
- 229920001353 Dextrin Polymers 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 235000019425 dextrin Nutrition 0.000 description 9
- 230000002496 gastric effect Effects 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 8
- 230000006378 damage Effects 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 8
- 238000010521 absorption reaction Methods 0.000 description 7
- 230000003908 liver function Effects 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 238000009825 accumulation Methods 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 230000001154 acute effect Effects 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 3
- 241000628997 Flos Species 0.000 description 3
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- 229930182816 L-glutamine Natural products 0.000 description 3
- 240000006365 Vitis vinifera Species 0.000 description 3
- 235000014787 Vitis vinifera Nutrition 0.000 description 3
- 229960003767 alanine Drugs 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000035622 drinking Effects 0.000 description 3
- 231100000753 hepatic injury Toxicity 0.000 description 3
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010019133 Hangover Diseases 0.000 description 2
- 108010044467 Isoenzymes Proteins 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 210000005252 bulbus oculi Anatomy 0.000 description 2
- 239000007910 chewable tablet Substances 0.000 description 2
- 229940068682 chewable tablet Drugs 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000004149 ethanol metabolism Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 1
- 235000007106 Crataegus suborbiculata Nutrition 0.000 description 1
- 241000073432 Crataegus suborbiculata Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 235000013202 a hawthorn Nutrition 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002075 anti-alcohol Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- RKHQGWMMUURILY-UHRZLXHJSA-N cortivazol Chemical compound C([C@H]1[C@@H]2C[C@H]([C@]([C@@]2(C)C[C@H](O)[C@@H]1[C@@]1(C)C2)(O)C(=O)COC(C)=O)C)=C(C)C1=CC1=C2C=NN1C1=CC=CC=C1 RKHQGWMMUURILY-UHRZLXHJSA-N 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- -1 lipid peroxides Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- VUZPPFZMUPKLLV-UHFFFAOYSA-N methane;hydrate Chemical compound C.O VUZPPFZMUPKLLV-UHFFFAOYSA-N 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明公开了一种解酒保肝作用的中药组合物及其制备方法。该组合物按重量份计主要由葛根10‑15份、枳椇子10‑15份、山楂4‑8份、菊花4‑8份和木糖醇19‑30份制成。制备方法包括以下步骤：取原料葛根、枳椇子、山楂和菊花，按料液比1g：5～10ml，加入水或50％～95％乙醇回流提取，提取液制成浸膏粉，粉碎后加入木糖醇，制成食品或适合于口服的药物制剂。本组合物的各组份协同作用发挥显著的解酒保肝作用，提高小鼠肝组织中乙醇脱氢酶(ADH)和乙醛脱氢酶(ALDH)的活性，降低血清中乙醇和乙醛的浓度，减轻酒精所致的肝损伤。所用原料既是食品又是中药材或食品添加剂，安全易得，价格低廉。The invention discloses a traditional Chinese medicine composition for relieving alcohol and protecting the liver and a preparation method thereof. The composition is mainly prepared from 10-15 parts of pueraria, 10-15 parts of Fructus aurantium, 4-8 parts of hawthorn, 4-8 parts of chrysanthemum and 19-30 parts of xylitol in parts by weight. The preparation method includes the following steps: taking raw materials Pueraria lobata, Fructus aurantium, hawthorn and chrysanthemum, adding water or 50%-95% ethanol for reflux extraction according to a material-to-liquid ratio of 1g: 5-10ml, the extract is made into extract powder, and crushed Add xylitol to make food or pharmaceutical preparations suitable for oral administration. The synergistic effect of each component of the composition plays a significant role in relieving alcoholism and protecting the liver, increasing the activities of alcohol dehydrogenase (ADH) and acetaldehyde dehydrogenase (ALDH) in the liver tissue of mice, and reducing the levels of ethanol and acetaldehyde in serum. Concentration, reduce alcohol-induced liver damage. The raw materials used are not only food, but also Chinese medicinal materials or food additives, which are safe and easy to obtain and low in price.
Description
Technical Field
The invention relates to a traditional Chinese medicine composition with the functions of dispelling effects of alcohol and protecting liver and a preparation method thereof.
Background
China is a large country for wine production and consumption, more than 2000 million tons of wine beverages are consumed every year, about 2 hundred million people are drunk or alcohol-dependent, and the acute and chronic alcoholism rate is increasingly higher.
Alcoholism is mainly caused by ethanol, the main component of wine, and metabolic disturbance thereof. The liver is the major site of ethanol metabolism. After ethanol enters the liver, it is first metabolized by Alcohol Dehydrogenase (ADH) to form acetaldehyde, which is then metabolized by acetaldehyde dehydrogenase (ALDH) to form acetic acid, which is finally broken down into carbon dioxide and water. In thatALDH plays an important role in the metabolism of acetaldehyde, but only ALDH having an oxidizing action in human body1And ALDH2Two isoenzymes, wherein ALDH2Is an isozyme with the strongest physiological activity in ALDH. The data show that 50% of Chinese are deficient in ALDH2After drinking, the concentration of acetaldehyde is easily increased and accumulated, so that the antigens of the liver cell membrane are changed, the metabolism of liver cells is disturbed, and free radicals, lipid peroxides and the like are generated. Failure to produce normal acetaldehyde dehydrogenase in vivo is one of the main causes of acute alcoholism and alcoholic liver disease in Chinese.
At present, the anti-alcoholism drugs on the market can be mainly classified into three categories according to the efficacy. The first is an alcohol absorption inhibitor, which uses alcohol dehydrogenase as a main component to metabolize alcohol in the gastrointestinal tract. The anti-alcoholism medicine is characterized in that the medicine is taken before drinking to reduce the amount of alcohol entering blood, and the medicine cannot clear ethanol and acetaldehyde, a metabolite of the ethanol, when taken after drinking. The second category is liver-protecting drugs, which mainly have a protective effect on the liver system, but have no obvious protective effect on other systems, such as the cardiovascular system. The third kind is an excitant, which enters into the body to produce corticoid stress effect and neutralize the inhibition of alcohol to the central nerve to sober up, but this kind of anti-alcoholism drug only treats the symptoms and not the root causes, and it will cause injury to the central nerve of human body after long-term use. In addition, none of the three anti-hangover agents has the efficacy of treating alcohol allergy. Therefore, the development of the rapid anti-alcohol liver-protecting medicine which is in line with the constitutional features of Chinese people, has comprehensive effects and few side effects and has important social significance and economic value.
Disclosure of Invention
In order to overcome the defects, the invention provides a composition for relieving alcoholism and protecting liver by improving the activities of alcohol dehydrogenase and acetaldehyde dehydrogenase and a preparation method thereof.
The composition is mainly prepared from 10-15 parts of kudzuvine root, 10-15 parts of hovenia dulcis thunb, 4-8 parts of hawthorn, 4-8 parts of chrysanthemum and 19-30 parts of xylitol according to parts by weight.
The preferable mixture ratio is 10 parts of kudzuvine root, 10 parts of hovenia dulcis thunb, 6 parts of hawthorn, 5 parts of chrysanthemum and 19 parts of xylitol.
The preparation method of the composition comprises the following steps: taking the raw materials of kudzu root, raisin tree seed, hawthorn and chrysanthemum according to the material-liquid ratio of 1 g: adding water or 50-95% ethanol into the mixture for reflux extraction, preparing extract powder from the extract, crushing the extract powder, adding xylitol, and preparing the product into food or pharmaceutical preparations suitable for oral administration.
The food can be made into jelly, tea or beverage; the medicinal preparation can be made into granule, capsule, granule, chewable tablet, tablet or oral liquid.
The composition can also be used for preparing medicaments or foods for improving the activity of acetaldehyde dehydrogenase and inhibiting the abnormal rise of glutamic-pyruvic transaminase or glutamic-pyruvic transaminase caused by alcohol.
The traditional Chinese medicine composition disclosed by the invention has the remarkable effects of dispelling the effects of alcohol and protecting the liver through the synergistic effect of the components, so that the activities of Alcohol Dehydrogenase (ADH) and acetaldehyde dehydrogenase (ALDH) in liver tissues of mice are improved, the concentrations of alcohol and acetaldehyde in serum are reduced, and the liver injury caused by alcohol is alleviated. The raw materials are food, Chinese medicinal materials or food additives, and are safe, easy to obtain and low in price. Can be used for preparing medicine or health food for improving alcohol dehydrogenase and acetaldehyde dehydrogenase activity to relieve hangover and protect liver, and can be used for preventing and treating acute alcoholic liver injury.
Detailed Description
The present invention will be further described with reference to the following examples.
The percentages of solids in the solid mixture, liquids in the liquids, and solids in the liquids referred to in the examples are calculated as wt/wt, vol/vol, wt/vol, respectively, unless otherwise indicated.
Example 1: the composition of the invention has the effects of relieving alcoholism and protecting liver
1. Material
1.1 Experimental animals
The SPF male Kunming mouse has the body mass of 18-20 g, is provided by Guangdong province medical experimental animal center, and has a qualification number: SCXK (Yue) 2013-.
1.2 drugs and reagents
The composition is prepared by taking 100g of kudzuvine root, 100g of hovenia dulcis thunb, 60g of hawthorn, 50g of chrysanthemum and 190g of xylitol, adding 8 times of 50 percent ethanol by volume, carrying out reflux extraction twice for 1 hour each time, filtering, combining the filtrates, concentrating, adding dextrin to prepare extract powder, drying, crushing, adding xylitol, and mixing uniformly. During the experiment, normal saline is prepared into solution with corresponding concentration for the mouse to use by gastric lavage. The administration dosage of mouse is 650mg crude drug/kg, converted according to body surface area, equivalent to 5g crude drug/day for 70kg adult, the crude drug is total amount of radix Puerariae, semen Hoveniae, fructus crataegi, flos Chrysanthemi, and xylitol.
Kudzu root extract: taking 100g of kudzuvine root, adding 50% ethanol with 8 times volume of the kudzuvine root, performing reflux extraction twice, filtering, combining filtrates of the two times, concentrating, adding dextrin and preparing extract powder. During the experiment, normal saline is prepared into solution with corresponding concentration for the mouse to use by gastric lavage. The administration dose of the mouse is 130mg crude drug/kg, which is equivalent to 1g crude drug/day of 70kg adult in terms of body surface area.
The raisin tree seed extract: taking 100g of semen hoveniae, adding 50 percent ethanol with 8 times volume of the semen hoveniae, carrying out reflux extraction twice, filtering, combining the filtrates, concentrating, adding dextrin, and preparing into extract powder. During the experiment, normal saline is prepared into solution with corresponding concentration for the mouse to use by gastric lavage. The administration dose of the mouse is 130mg crude drug/kg, which is equivalent to 1g crude drug/day of 70kg adult in terms of body surface area.
And (3) hawthorn extract: 60g of hawthorn is taken, added with 50 percent ethanol with 8 times of volume and extracted twice under reflux, filtered, the two filtrates are combined, concentrated and added with dextrin to prepare extract powder. During the experiment, normal saline is prepared into solution with corresponding concentration for the mouse to use by gastric lavage. The administration dose of the mouse is 78mg crude drug/kg, which is equivalent to 0.60g crude drug/day of 70kg adult in terms of body surface area.
And (3) chrysanthemum extract: taking 50g of chrysanthemum, adding 50% ethanol with 8 times of volume, carrying out reflux extraction twice, filtering, combining filtrates of the two times, concentrating, adding dextrin, and preparing into extract powder. During the experiment, normal saline is prepared into solution with corresponding concentration for the mouse to use by gastric lavage. The administration dose of the mouse is 65 mg/kg of crude drug, which is equivalent to 0.5 g/day of crude drug of 70kg of adult in terms of body surface area.
Xylitol: during the experiment, normal saline is prepared into solution with corresponding concentration for the mouse to use by gastric lavage. The dose of administration to mice was 247mg/kg, which corresponds to 1.9 g/day for a 70kg adult, in terms of body surface area.
Comparative composition 1: taking 100g of kudzuvine root, 100g of hovenia dulcis thunb, 60g of hawthorn and 50g of chrysanthemum, adding 50 percent ethanol with the volume being 8 times of that of the kudzuvine root, refluxing and extracting for two times, each time for 1 hour, filtering, combining the two filtrates, concentrating, adding dextrin and preparing the dextrin into extract powder. During the experiment, normal saline is prepared into solution with corresponding concentration for the mouse to use by gastric lavage. The administration dosage of the mouse is 403mg crude drug/kg, which is equivalent to 3.1g crude drug/day of 70kg adult in terms of body surface area, and the crude drug is the total amount of radix Puerariae, semen Hoveniae, fructus crataegi and flos Chrysanthemi.
Comparative composition 2: taking 100g of kudzuvine root, 100g of hovenia dulcis thunb, 60g of hawthorn, 50g of chrysanthemum, 30g of L-alanine and 40g of L-glutamine, adding 50 percent ethanol with the volume being 8 times of that of the kudzuvine root, refluxing and extracting for two times, each time for 1 hour, filtering, combining the two filtrates, concentrating, adding dextrin to prepare extract powder, crushing, adding the L-alanine and the L-glutamine, and uniformly mixing. During the experiment, normal saline is prepared into solution with corresponding concentration for the mouse to use by gastric lavage. The administration dosage of mouse is 650mg crude drug/kg, converted according to body surface area, equivalent to 5g crude drug/day for 70kg adult, the crude drug is total amount of radix Puerariae, semen Hoveniae, fructus crataegi, flos Chrysanthemi, L-alanine and L-glutamine.
Positive control (Pepp conscious chewable tablet): purchased from shandeshi company. Taking the Pepp sober-minded tablets, grinding, and preparing a solution with a corresponding concentration by using normal saline for gastric lavage of the mice. The mouse dose is 8320mg/kg, converted from body surface area, which is equivalent to 64 g/day (equivalent to 8 times the clinical equivalent dose) for 70kg of adults.
56 degree red star Erguotou (Beijing red star GmbH); absolute ethanol (mao chemical reagents works, Tianjin); 40% acetaldehyde (Chengdu Kelong chemical reagent plant); butanone (Baishi chemical Co., Tianjin); alcohol Dehydrogenase (ADH) and acetaldehyde dehydrogenase (ALDH) kits (Nanjing, Biotechnology Ltd.); alanine Aminotransferase (ALT) kit and aspartate Aminotransferase (AST) kit (Nanjing Biotechnology Co., Ltd.); physiological saline (Kunming Yusi pharmaceutical Co., Ltd.)
1.3 Main instruments
Gas chromatograph: varian CP-3800; a workstation: CTC analytical; a chromatographic column: CP-Wax52CB, Cpsil5CB-2 capillary column; a detector: a FID detector; general UV spectrophotometer for Beijing UV-1 chromatography.
2. Method of producing a composite material
The SPF-grade healthy Kunming mice are randomly divided into 11 groups: a normal control group, a model control group, a composition group of the invention, a radix puerariae extract group, a hovenia dulcis thunb extract group, a hawthorn extract group, a chrysanthemum extract group, a xylitol group, a comparative composition 1 group, a comparative composition 2 group and a positive control group, wherein each group comprises 12 animals. Each group of animals was administered by gavage, and the blank control group and the model control group were given equal volume of distilled water for 1 time/day. 1h after each administration, the mice of other groups except the blank control group are subjected to intragastric administration according to 0.12ml/10g to 56-degree Hongxing Erguotou to cause acute alcoholic liver injury model, and continuous administration and model building are carried out for 6 d. 1.5h after the last molding, 0.5-1 ml of blood is taken from each group of eyeballs, serum is separated by centrifuging at 3000rpm for 10min, the concentration of ethanol and acetaldehyde in the serum is measured by adopting a gas chromatograph, and the AST and ALT activity of the serum is measured according to the operation method of the kit. After the eyeballs are picked and blood is taken, the cervical vertebra is dislocated immediately to kill the mice, 0.5g of fresh liver is taken and added with precooled physiological saline solution to prepare 10% liver tissue homogenate, the homogenate is centrifuged at 3000rpm for 10min, and the supernatant is taken to determine the activity of ADH and ALDH.
The statistical processing method adopts SPSS13.0 statistical software, and data are expressed by mean plus or minus standard deviation
Showing that the comparison among groups adopts one-factor variance analysis, the comparison between two groups is checked by LSD, P<A difference of 0.05 is statistically significant.
3. Results
3.1 Effect of the compositions of the invention on the serum ethanol and acetaldehyde concentration in mice
As can be seen from Table 1, compared with the normal control group, the concentrations of ethanol and acetaldehyde in the serum of the mice in the model group are significantly increased, and the difference has statistical significance (P <0.01), which indicates that the modeling method can successfully cause the significant increase of the concentrations of ethanol and acetaldehyde in the serum of the mice.
Compared with a model control group, the concentration of ethanol and acetaldehyde in the serum of the mice of the composition group is obviously reduced, and the difference has statistical significance (P <0.01), which indicates that the composition can obviously inhibit the absorption of ethanol, promote the metabolism of ethanol and reduce the accumulation of acetaldehyde. Compared with the model control group, the concentrations of ethanol and acetaldehyde in the serum of the mice of the comparison composition 1 group, the comparison composition 2 group and the positive control group are obviously reduced, and the difference has statistical significance (P <0.05 or P < 0.01); the concentration of ethanol and acetaldehyde in mouse serum of the pueraria extract group, the hovenia dulcis thunb extract group, the hawthorn extract group, the chrysanthemum extract group and the xylitol group is not significantly different from that of the model control group and has no statistical significance (P >0.05), which indicates that the comparison composition 1, the comparison composition 2 and the positive control can significantly inhibit the absorption of ethanol or promote the metabolism of ethanol and reduce the accumulation of acetaldehyde, while the pueraria extract group, the hovenia dulcis thunb extract group, the hawthorn extract, the chrysanthemum extract and the xylitol can not significantly inhibit the absorption of ethanol or promote the metabolism of ethanol and can not reduce the accumulation of acetaldehyde.
Compared with the composition group of the invention, the concentrations of ethanol and acetaldehyde in the serum of mice in the kudzu root extract group, the hovenia dulcis thunb extract group, the hawthorn extract group, the chrysanthemum extract group, the xylitol group, the comparative composition 1 group and the comparative composition 2 group are obviously higher, and the difference has statistical significance (P <0.05 or P < 0.01); the concentration of ethanol and acetaldehyde in the serum of mice of the positive control group is not significantly different from that of the composition group of the invention (P >0.05), which indicates that the composition of the invention is superior to the pueraria extract, the hovenia dulcis thunb extract, the hawthorn extract, the chrysanthemum extract, the xylitol, the comparative composition 1 and the comparative composition 2 in the aspects of inhibiting ethanol absorption or promoting ethanol metabolism and reducing the accumulation of acetaldehyde, and is equivalent to the positive control.
3.2 Effect of the compositions of the invention on the serum AST and ALT Activity in mice
As can be seen from Table 2, compared with the normal control group, the serum AST and ALT activities of the mice in the model group are obviously increased, and the difference has statistical significance (P <0.01), which indicates that the modeling method can successfully cause the liver function damage of the mice.
Compared with a model control group, the mouse serum AST and ALT activities of the composition group are obviously reduced, and the difference has statistical significance (P <0.01), which indicates that the composition can obviously inhibit the liver function damage caused by alcohol. Compared with the model control group, the AST and ALT activities in the blood serum of the mice of the control composition 1 group, the control composition 2 group and the positive control group are obviously reduced, and the difference has statistical significance (P <0.05 or P < 0.01); the AST and ALT activities in the mouse serum of the radix puerariae extract group, the hovenia dulcis thunb extract group, the hawthorn extract group, the chrysanthemum extract group and the xylitol group are not obviously different from those of the model control group, and have no statistical significance (P >0.05), so that the comparison composition 1, the comparison composition 2 and the positive control can obviously inhibit the liver function damage caused by alcohol, and the radix puerariae extract group, the hovenia dulcis thunb extract group, the hawthorn extract, the chrysanthemum extract and the xylitol can not obviously inhibit the liver function damage caused by alcohol.
Compared with the composition group of the invention, the mouse serum AST and ALT activities of the radix puerariae extract group, the hovenia dulcis thunb extract group, the hawthorn extract group, the chrysanthemum extract group, the xylitol group, the comparative composition 1 group, the comparative composition 2 group and the positive control group are obviously higher, and the difference has statistical significance (P <0.05 or P <0.01), which indicates that the composition of the invention is superior to the radix puerariae extract, the hovenia dulcis thunb extract, the hawthorn extract, the chrysanthemum extract, the xylitol, the comparative composition 1, the comparative composition 2 and the positive control in the aspect of inhibiting the liver function damage caused by alcohol.
3.3 Effect of the compositions of the invention on ADH and ALDH activity in mouse liver
As can be seen from Table 3, compared with the normal control group, the ADH and ALDH activities in the mouse livers of the model group are significantly reduced, and the difference has statistical significance (P <0.01), which indicates that the modeling method can successfully cause the reduction of the metabolic capability of the mouse livers to ethanol and acetaldehyde.
Compared with a model control group, the activity of ADH and ALDH in the liver of a mouse of the composition group is obviously improved, and the difference has statistical significance (P <0.01), so that the composition can obviously improve the activity of ADH and ALDH in the liver and obviously promote the metabolism of the liver to ethanol and acetaldehyde. The ADH and ALDH activity was significantly increased in the livers of mice of the control composition 1 group and the control composition 2 group compared to the model control group, the difference being statistically significant (P <0.05 or P < 0.01); the activities of ADH and ALDH in mouse livers of the kudzu root extract group, the hovenia dulcis thunb extract group, the hawthorn extract group, the chrysanthemum extract group, the xylitol group and the positive control group are not obviously different from those of the model control group and have no statistical significance (P >0.05), which indicates that the comparative composition 1 and the comparative composition 2 can obviously improve the activities of ADH and ALDH in livers and obviously promote the metabolism of alcohol and acetaldehyde by livers, while the kudzu root extract group, the hovenia dulcis thunb extract group, the hawthorn extract, the chrysanthemum extract, xylitol and the positive control group cannot obviously improve the activities of ADH and ALDH in livers and cannot obviously promote the metabolism of alcohol and acetaldehyde by livers.
Compared with the composition group of the invention, the mouse livers of the pueraria extract group, the hovenia dulcis thunb extract group, the hawthorn extract group, the chrysanthemum extract group, the xylitol group, the comparative composition 1 group, the comparative composition 2 group and the positive control group have obviously lower ADH and ALDH activities, and the difference has statistical significance (P <0.05 or P <0.01), which indicates that the composition of the invention is superior to the pueraria extract, the hovenia dulcis thunb extract, the hawthorn extract, the chrysanthemum extract, xylitol, the comparative composition 1, the comparative composition 2 and the positive control in improving the ADH and ALDH activities in the livers and promoting the metabolism of the livers to ethanol and acetaldehyde.
TABLE 1 mouse serum ethanol, acetaldehyde content
Note: compared with the normal control group, the composition has the advantages that,**p<0.01; compared with the model control group,#p<0.05，##p<0.01; in comparison with the composition group of the present invention,△p<0.05，△△p<0.01。
TABLE 2 mouse serum AST and ALT Activity
Note: compared with the normal control group, the composition has the advantages that,**p<0.01; compared with the model control group,#p<0.05，##p<0.01; in comparison with the composition group of the present invention,△p<0.05，△△p<0.01。
TABLE 3 mouse liver tissue ADH and ALDH Activity
Note: compared with the normal control group, the composition has the advantages that,**p<0.01; compared with the model control group,#p<0.05，##p<0.01; in comparison with the composition group of the present invention,△p<0.05，△△p<0.01。
4. summary of the invention
At the dosage of the embodiment, the composition of the invention can significantly inhibit the absorption of ethanol or promote the metabolism of ethanol and reduce the accumulation of acetaldehyde, and the composition of the invention is superior to pueraria extract, hovenia dulcis thunb extract, hawthorn extract, chrysanthemum extract, xylitol, comparative composition 1 and comparative composition 2 in terms of inhibiting the absorption of ethanol or promoting the metabolism of ethanol and reducing the accumulation of acetaldehyde, and is equivalent to a positive control; the composition can obviously inhibit liver function damage caused by alcohol, and is superior to kudzu root extract, hovenia dulcis thunb extract, hawthorn extract, chrysanthemum extract, xylitol, comparative composition 1, comparative composition 2 and positive control in inhibiting liver function damage caused by alcohol; the composition can obviously improve the activity of ADH and ALDH in the liver and promote the metabolism of the liver to ethanol and acetaldehyde, and is superior to kudzu root extract, hovenia dulcis thunb extract, hawthorn fruit extract, chrysanthemum extract, xylitol, comparative composition 1, comparative composition 2 and positive control in the aspects of improving the activity of ADH and ALDH in the liver and promoting the metabolism of the liver to ethanol and acetaldehyde.
Example 2 comparison of drug effects of different extraction methods
Taking four medicinal materials and xylitol. The medicinal materials are divided into 5 parts, each part comprises 100g of kudzuvine root, 100g of raisin tree seed, 60g of hawthorn and 50g of chrysanthemum, and are respectively extracted by 8 times of water, 25% ethanol, 50% ethanol, 75% ethanol and 95% ethanol under reflux, the two parts are respectively extracted for 1 hour each time, filtered, the two filtrates are combined, concentrated, dextrin is added to prepare extract powder, 190g of xylitol is added after drying and crushing, and the mixture is uniformly mixed. For use, experiments were performed according to the experimental method of example 2. And extracting the sample group by using a normal control group, a model control group, water, 25% ethanol, 50% ethanol, 75% ethanol and 95% ethanol.
The results show that the effect is not obviously influenced by adopting water extraction and alcohol extraction. The results are as follows:
TABLE 4 mouse serum ethanol, acetaldehyde content
Note: compared with the normal control group, the composition has the advantages that,**p<0.01; compared with the model control group,##p<0.01。
TABLE 5 mouse serum AST and ALT Activity
Note: compared with the normal control group, the composition has the advantages that,**p<0.01; compared with the model control group,##p<0.01。
TABLE 6 mouse liver tissue ADH and ALDH Activity
Note: compared with the normal control group, the composition has the advantages that,**p<0.01; compared with the model control group,##p<0.01。
example 3 comparison of drug effects of different raw material ratios
The preparation method comprises the steps of taking four medicinal materials and xylitol, dividing the medicinal materials into three parts, wherein ① is 100g of kudzuvine root, 100g of hovenia dulcis thunb, 40g of hawthorn, 40g of chrysanthemum and 300 g of xylitol, ② is 150g of kudzuvine root, 150g of hovenia dulcis thunb, 80g of hawthorn, 80g of chrysanthemum and 250 g of xylitol, ③ is 100g of kudzuvine root, 100g of hovenia dulcis thunb, 60g of hawthorn, 50g of chrysanthemum and 190g of xylitol, respectively adopting the methods of the embodiment 2 and the embodiment 3 for treatment to serve as sample samples, carrying out experiment according to the experiment method of the embodiment 2, setting a normal control group, a model control group, ①, ② and ③ sample extraction groups, and the dosage of the samples is the same as the original drug.
However, compared with data, ③ extracts a sample group, namely when 10 parts of kudzuvine root, 10 parts of hovenia dulcis thunb, 6 parts of hawthorn, 5 parts of chrysanthemum and 19 parts of xylitol, the effect is better, especially in the aspect of improving the activity of liver tissue ADH and ALDH, compared with ③ extracts the sample group, ① extracts samples, ② extracts the sample group with lower activity of ADH and ALDH and statistical difference (P <0.05 or P <0.01), which shows that in ①, ② and ③ extracts the sample group, ③ extracts have stronger antialcoholism and hepatoprotective effects, and the results are as follows:
TABLE 7 serum ethanol, acetaldehyde content of mice
Note: compared with the normal control group, the composition has the advantages that,**p<0.01; compared with the model control group,##p<0.01。
TABLE 8 serum AST and ALT Activity in mice
Note: compared with the normal control group, the composition has the advantages that,**p<0.01; compared with the model control group,##p<0.01。
TABLE 9 mouse liver tissue ADH and ALDH Activity
Note: compared with the normal control group, the composition has the advantages that,**p<0.01; compared with the model control group,##p<0.01, compared to the ③ extraction group,△p<0.05，△△p<0.01。
Claims (5)
1. the traditional Chinese medicine composition for improving the activity of the ethanol dehydrogenase is characterized by being prepared from the following raw materials in parts by weight: 10-15 parts of kudzuvine root, 10-15 parts of hovenia dulcis thunb, 4-8 parts of hawthorn, 4-8 parts of chrysanthemum and 19-30 parts of xylitol.
2. The traditional Chinese medicine composition of claim 1, wherein the mixture ratio of the raw materials is as follows: 10 parts of kudzuvine root, 10 parts of hovenia dulcis thunb, 6 parts of hawthorn, 5 parts of chrysanthemum and 19 parts of xylitol.
3. The preparation method of the traditional Chinese medicine composition of claim 1, comprising the following steps: 1g of radix puerariae, semen hoveniae, hawthorn and chrysanthemum in a material-liquid ratio: adding water or 50-95% ethanol into the mixture for reflux extraction, preparing extract powder from the extract, crushing the extract powder, adding xylitol, and preparing the oral pharmaceutical preparation.
4. The use of the Chinese medicinal composition of claim 1 or 2 in the preparation of a medicament for inhibiting the abnormal increase of glutamate pyruvate transaminase caused by alcohol.
5. The use of the Chinese medicinal composition of claim 1 or 2 in the preparation of a medicament for inhibiting abnormal increase of glutamic-oxaloacetic transaminase caused by alcohol.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710443629.7A CN107050148B (en) | 2017-06-13 | 2017-06-13 | Traditional Chinese medicine composition for dispelling effects of alcohol and protecting liver and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710443629.7A CN107050148B (en) | 2017-06-13 | 2017-06-13 | Traditional Chinese medicine composition for dispelling effects of alcohol and protecting liver and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107050148A CN107050148A (en) | 2017-08-18 |
| CN107050148B true CN107050148B (en) | 2020-06-02 |
Family
ID=59594895
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710443629.7A Active CN107050148B (en) | 2017-06-13 | 2017-06-13 | Traditional Chinese medicine composition for dispelling effects of alcohol and protecting liver and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107050148B (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108669532A (en) * | 2018-04-03 | 2018-10-19 | 周耀强 | A kind of prescription and production method effectively improving internal acetaldehyde dehydrogenase |
| CN110074243A (en) * | 2019-04-29 | 2019-08-02 | 海南路易丹尼生物科技有限公司 | It is a kind of with relieving the effect of alcohol and protect the pressed candy of liver function |
| CN112569323A (en) * | 2020-12-31 | 2021-03-30 | 上海交大昂立股份有限公司 | Composition for dispelling effects of alcohol and protecting liver and application thereof |
| CN113456725A (en) * | 2021-06-17 | 2021-10-01 | 浙江天一堂医药管理有限公司 | Product for relieving alcoholism and preparation method thereof |
| CN113413453A (en) * | 2021-07-28 | 2021-09-21 | 福建中医药大学 | Composition for relieving alcoholism and protecting liver |
| CN114891808B (en) * | 2022-06-21 | 2023-10-27 | 珠海丽凡达生物技术有限公司 | mRNA molecule encoding ALDH2 polypeptide, application and mRNA medicament |
| CN115154556A (en) * | 2022-07-21 | 2022-10-11 | 深圳市久久为功健康产业发展有限公司 | A Chinese medicinal composition with anti-hangover effect, and its preparation method |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102578671A (en) * | 2012-03-20 | 2012-07-18 | 牟一心 | Alcoholism-relieving liver-protecting botanical nutritional beverage and making method thereof |
| CN102727661A (en) * | 2012-07-18 | 2012-10-17 | 张立峰 | Capsule for alleviating hangover and protecting liver and preparation method thereof |
| CN103285252A (en) * | 2012-12-27 | 2013-09-11 | 福建永生活力生物工程有限公司 | Oral liquid for alleviating hangover and protecting liver, and preparation method thereof |
| CN105520010A (en) * | 2015-12-04 | 2016-04-27 | 重庆三零三科技有限公司 | Liver protecting and alcoholism dispelling nutritional and health-care drink |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102284020A (en) * | 2011-07-07 | 2011-12-21 | 中山大学 | Composite with actions of relieving alcoholism and protecting liver and preparation method and applications thereof |
| CN103494193A (en) * | 2013-09-12 | 2014-01-08 | 北京中科邦尼国际科技有限责任公司 | Plant extract for dispelling effects of alcohol and protecting liver as well as application thereof in food and healthcare food |
| CN104082722A (en) * | 2014-06-10 | 2014-10-08 | 胡安然 | Micro-ecologic preparation for preventing and treating hepatitis |
-
2017
- 2017-06-13 CN CN201710443629.7A patent/CN107050148B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102578671A (en) * | 2012-03-20 | 2012-07-18 | 牟一心 | Alcoholism-relieving liver-protecting botanical nutritional beverage and making method thereof |
| CN102727661A (en) * | 2012-07-18 | 2012-10-17 | 张立峰 | Capsule for alleviating hangover and protecting liver and preparation method thereof |
| CN103285252A (en) * | 2012-12-27 | 2013-09-11 | 福建永生活力生物工程有限公司 | Oral liquid for alleviating hangover and protecting liver, and preparation method thereof |
| CN105520010A (en) * | 2015-12-04 | 2016-04-27 | 重庆三零三科技有限公司 | Liver protecting and alcoholism dispelling nutritional and health-care drink |
Non-Patent Citations (4)
| Title |
|---|
| 【PePP清醒咀嚼片】说明书 原包装;净香妆园;《http://blog.sina.com.cn/s/blog_dc95a7240102v1ag.html》;20140813;第1-2页 * |
| 木糖醇可以解酒吗？;lhqxyg;《https://zhidao.baidu.com/question/85430594.html》;20090210;第1-2页 * |
| 糖尿病的人能吃解酒药吗？;热心网友;《https://muzhi.baidu.com/question/2265504964638118588.html》;20130413;第1页 * |
| 药食两用说葛根;胡献国;《东方药膳》;20061231(第6期);第43-44页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107050148A (en) | 2017-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107050148B (en) | Traditional Chinese medicine composition for dispelling effects of alcohol and protecting liver and preparation method thereof | |
| CN101152007B (en) | A kind of health product composition and preparation method thereof | |
| CN103656286B (en) | Alleviate compositions and the application of discomfort and reduction alcoholic liver injury after drinking | |
| CN102284020A (en) | Composite with actions of relieving alcoholism and protecting liver and preparation method and applications thereof | |
| CN102846771A (en) | Composition with antialcoholism and hepatoprotective effect | |
| CN103143003A (en) | Healthcare product for relieving hangover and protecting liver | |
| CN102178885B (en) | Medicinal composition for sobering | |
| CN101284064A (en) | Preparation method of kudzuvine root and indigowoad root tablets for reducing fat and alleviating hangover | |
| CN105707765A (en) | Liver protection plant oral liquid and preparation method thereof | |
| WO2012016384A1 (en) | Anti-fatigue composition of plant material and preparation method, use and products thereof | |
| CN102552692B (en) | Anoectochilus formosanus compound alcohol-relieving and liver-protecting capsule and preparation method thereof | |
| CN112618608A (en) | Composition with function of dispelling effects of alcohol and preparation method and application thereof | |
| CN106727902B (en) | Chinese medicinal composition for hangover and liver protection containing Cordyceps sinensis and its application | |
| CN102462740B (en) | Medicinal composition for dispelling effects of alcohol and protecting liver and preparation method thereof | |
| CN116138455A (en) | Panax notoginseng polysaccharide extract and its application in the preparation of anti-fatigue products | |
| CN107951030A (en) | A kind of compound granule with Antialcoholic liver-protecting and preparation method thereof | |
| CN104013696B (en) | A kind of plant drug composition of preventing and treating metabolism syndrome and its application | |
| CN105747217A (en) | Dendrobium candidum composition and application and preparation method thereof | |
| CN112007092A (en) | Anti-alcohol composition and preparation method thereof | |
| CN104886252A (en) | Compound traditional Chinese medicine antialcoholic yogurt and preparation technology thereof | |
| CN104857180A (en) | Anti-fatigue and immunity-improving composition as well as preparation method and application thereof | |
| CN105168519B (en) | With the composition and its preparation method and application for improving sleep function | |
| CN102631486B (en) | Health care composition | |
| CN114668830B (en) | Anti-alcohol and liver-protecting composition and preparation method thereof | |
| CN102631506B (en) | Traditional Chinese medicine composition capable of improving immunity and resisting fatigue |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |